Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

After climbing by 19% over the last year, KXS stock currently trades at $199.23 per share with a market cap of $5.6 billion.